Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VCYT 
Veracyte Inc (VCYT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VCYT (3-star) is a STRONG-BUY. BUY since 2 days. Profits (-2.09%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $39.62
1 Year Target Price $39.62
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.46% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio 82.32 | 1Y Target Price 39.62 |
Price to earnings Ratio 82.32 | 1Y Target Price 39.62 | ||
Volume (30-day avg) 11 | Beta 1.97 | 52 Weeks Range 22.61 - 47.32 | Updated Date 08/11/2025 |
52 Weeks Range 22.61 - 47.32 | Updated Date 08/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.1057 | Actual 0.44 |
Profitability
Profit Margin 5.5% | Operating Margin (TTM) 11% |
Management Effectiveness
Return on Assets (TTM) 1.98% | Return on Equity (TTM) 2.24% |
Valuation
Trailing PE 82.32 | Forward PE 18.55 | Enterprise Value 1883168363 | Price to Sales(TTM) 4.6 |
Enterprise Value 1883168363 | Price to Sales(TTM) 4.6 | ||
Enterprise Value to Revenue 3.93 | Enterprise Value to EBITDA 36.25 | Shares Outstanding 78314600 | Shares Floating 78226307 |
Shares Outstanding 78314600 | Shares Floating 78226307 | ||
Percent Insiders 0.53 | Percent Institutions 106.44 |
Upturn AI SWOT
Veracyte Inc
Company Overview
History and Background
Veracyte, Inc. was founded in 2008 and is a genomic diagnostics company based in South San Francisco, California. It focuses on developing and commercializing genomic tests that improve patient outcomes and reduce unnecessary procedures.
Core Business Areas
- Genomic Diagnostics: Develops and commercializes genomic tests for thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis.
- Biopharma Services: Provides genomic services to biopharmaceutical companies to support drug development and clinical trials.
Leadership and Structure
Marc Stapley is the CEO. The company has a board of directors and a management team responsible for different functional areas.
Top Products and Market Share
Key Offerings
- Afirma Genomic Sequencing Classifier (GSC): A genomic test for thyroid nodules to determine if they are benign or suspicious for cancer. The Afirma GSC has a significant market share in thyroid nodule testing, competing with traditional cytology. Competitors include Interpace Biosciences, and other molecular testing companies.
- Percepta Genomic Sequencing Classifier (GSC): A genomic test for lung nodules to help determine if they are benign or malignant. Competitors include Biodesix, and other diagnostic companies.
- Envisia Genomic Classifier: A test used to identify patients with idiopathic pulmonary fibrosis (IPF). Competitors include other diagnostic labs offering tests in the respiratory disease area.
- Decipher Biopsy and GRID: Genomic tests used in prostate and breast cancer for prognostic information and therapy selection. Competitors include Exact Sciences.
Market Dynamics
Industry Overview
The genomic diagnostics industry is rapidly growing, driven by advancements in genomics, increasing demand for personalized medicine, and the need for more accurate diagnostic tests.
Positioning
Veracyte is a leader in genomic diagnostics, focusing on developing and commercializing innovative tests for specific diseases. The company differentiates itself through its focus on high-value clinical applications and its strong relationships with clinicians and biopharmaceutical companies.
Total Addressable Market (TAM)
The TAM for genomic diagnostics is estimated to be billions of dollars and is expected to continue to grow. Veracyte is positioned to capture a significant share of this market with its existing products and pipeline of new tests.
Upturn SWOT Analysis
Strengths
- Strong portfolio of genomic diagnostic tests
- Established commercial infrastructure
- Strong relationships with clinicians and biopharmaceutical companies
- Proprietary technology platform
Weaknesses
- Reliance on reimbursement from payers
- Competition from other genomic diagnostic companies
- Potential for regulatory changes
Opportunities
- Expansion into new disease areas
- Development of companion diagnostics for new therapies
- Partnerships with biopharmaceutical companies
- International expansion
Threats
- Changes in reimbursement policies
- Increased competition
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- ESMO
- EXAS
- PACB
Competitive Landscape
Veracyte competes with other genomic diagnostic companies, as well as traditional diagnostic methods. Veracyte's competitive advantages include its strong portfolio of genomic tests, its established commercial infrastructure, and its strong relationships with clinicians and biopharmaceutical companies.
Major Acquisitions
HalioDx
- Year: 2021
- Acquisition Price (USD millions): 260
- Strategic Rationale: Expanded Veracyte's portfolio in cancer diagnostics and precision oncology, particularly in the field of immuno-oncology.
Decipher Biosciences
- Year: 2021
- Acquisition Price (USD millions): 600
- Strategic Rationale: Expanded Veracyte's portfolio in urology and oncology, providing prognostic information and therapy selection tools.
Growth Trajectory and Initiatives
Historical Growth: Veracyte has experienced strong revenue growth in recent years, driven by increasing adoption of its genomic tests.
Future Projections: Analysts project continued revenue growth for Veracyte, driven by new product launches and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of new genomic tests and partnerships with biopharmaceutical companies.
Summary
Veracyte is a growing genomic diagnostics company with a strong portfolio of products and a solid commercial infrastructure. They have increased revenue growth due to its existing products and new product expansions. They have also acquired many different companies which expanded the business and has continued success. Reimbursement policies and competition are factors that the company needs to be careful on.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- Third-party market research reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veracyte Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2013-10-30 | CEO & Director Mr. Marc A. Stapley | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 824 | Website https://www.veracyte.com |
Full time employees 824 | Website https://www.veracyte.com | ||
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.